Seattle Genetics, Inc.

Merrimack Pharmaceuticals, Inc.

Seagen Inc.

Charlotte McDonagh

Paul J Carter

Dennis R Benjamin

Charles G Cerveny

Che-Leung Law

Julie A McEarchern

Alexandra Huhalov

Michael Feldhaus

Django Sussman

Bo Zhang

Hans Peter Gerber

Leigh Francisco

This invention, among other things, relates to CD19 binding agents and methods of using such CD binding agents for treating disease.

CD19 binding agents and uses thereof

This invention relates to CD19 binding agents and methods of using such CD19 binding agents for treating disease.

Disclosed are CD70 binding agents, such as humanized anti-CD70 antibodies and fragments and derivatives, that exert a cytotoxic, cytostatic or immunomodulatory on CD70 expressing cells, as well as pharmaceutical compositions and kits comprising the antibody, fragment or derivative. Also disclosed are methods for the treatment of CD70-expressing cancers and immunological disorders, comprising administering to a subject the CD70 binding agents or pharmaceutical compositions.

Humanized anti-CD70 binding agents and uses thereof

Disclosed are methods and compositions for inhibiting the growth of a tumor (e.g., a malignant tumor) in a subject. In particular, combination therapies for treating a tumor in a subject by co-administering an agent selected from i) an effective amount of an anti-estrogen agent; ii) an effective amount of a receptor tyrosine kinase inhibitor; iii) an effective amount of a MEK/PI3 kinase/AKT inhibitor; iv) an effective amount of MM-151; v) an effective amount of an mTOR inhibitor; and/or vi) an effective amount of trastuzumab or TMD1, and/or combinations thereof; and an effective amount of a bispecific anti-ErbB2/anti-ErbB3 antibody. Also disclosed is a bispecific anti-ErbB2/anti-ErbB3 antibody for use in the therapy of a tumor in combination with an agent selected from i) an effective amount of an anti-estrogen agent; ii) an effective amount of a receptor tyrosine kinase inhibitor; iii) an effective amount of a MEK/PI3 kinase/AKT inhibitor; iv) an effective amount of MM-151; v) an effective amount of an mTOR inhibitor; and/or vi) an effective amount of trastuzumab or TMD1, and/or combinations thereof.

Combination therapies comprising anti-ERBB3 agents

This invention, inter alia, relates to CD19 binding agents and methods of using such CD19 binding agents for treating disease.

Disclosed is a human serum albumin (HSA) linker and HSA linker with binding, diagnostic, and therapeutic agents conjugated thereto. Also disclosed is a conjugate in which the HSA linker is covalently bonded to amino and carboxy terminal binding moieties that are first and second single-chain Fv molecules (scFvs). Exemplified conjugates are useful, e.g., in reducing tumor cell proliferation, e.g., for therapeutic therapeutic applications. Also disclosed are methods and kits for the diagnostic and therapeutic application of an HSA linker conjugate.

Human serum albumin linkers and conjugates thereof

The present invention provides variant target binding agents and methods relating to the use of such binding agents for the prophylaxis or treatment of cancers and immunological disorders. The variant target binding agent is conjugated to a therapeutic agent that exerts a cytotoxic, cytostatic, or immunomodulatory effect on target cells.

Variant target binding agents and uses thereof

This invention relates to CD30 binding agents and methods of using such binding agents for treating disease characterized by expression of CD30 antigen.

CD30 binding agents and uses thereof

This invention relates to CD 19 binding agents and methods of using such CD 19 binding agents for treating disease.

Growing community of inventors

Waltham, MA, United States of America

Charlotte McDonagh